### **Light House Update**

#### Sector - Chemicals WAY2WEALTH

Research Desk 🗢 🖛

12<sup>th</sup> November 2021

CMP - ₹939/-

View - Accumulate on dips

**Q2FY22** Performance

- During the guarter, Aarti Industries Ltd reported 32% Y-o-Y & 18% Q-o-Q topline growth on the back of strong growth in specialty chemicals segment up by 34% Y-o-Y & 17% Q-o-Q, pharmaceuticals up by 26% Y-o-Y & 16% Q-o-Q and higher contribution from value-added products.
- EBITDA at ₹3098mn, grew by ~22% Y-o-Y however EBITDA margins fell to 20%  $\geq$ from ~22% on account of higher input prices (specially benzene prices).
- Profit after tax grew by ~23% Y-o-Y to ₹1761mn driven by growth in EBITDA, aided by reduction in finance cost (down 17% Y-o-Y).
- Capex in Q2FY22 stands at ₹3170mn; while 6M aggregate capex of ₹6200mn is in line with guidance of ₹12000-15000mn for FY22E.

#### **Key Concall Highlights**

- Company has reiterated revenue/PAT growth guidance of 25% for FY22.  $\geq$
- Specialty chemicals business segment revenues were up 34% Y-o-Y & 17% Q-o- $\triangleright$ Q to ₹14835mn, followed by pharmaceuticals revenue increased 26% Y-o-Y & 16% Q-o-Q largely led by realization growth. Margins in the pharma business were impacted owing to delay in the passing of input price inflation.
- Company's long-term projects got delayed due to Covid related challenges, however it targets to commercialize second contract by Q3FY22 and third contract by Q1FY23.
- Company would be launching new products like chlorotoluene and its  $\geq$ downstream and value-added products in NCB towards FY24-end.
- Discontinuation of MEIS and non-inclusion of Chemical & Pharma products under RotDep Scheme impacts the sector negatively.
- The company has received income of around US\$7 million towards the shortfall  $\geq$ fees in respect of the first long term contract.
- In pharmaceutical segment, the company has started working with innovators at  $\geq$ various stages like R&D and design. Some of the construction is expected in FY22- end and others in FY23.
- Capex for FY22E-24E stands at ₹45000-50000mn and for existing products stands at ₹15000mn and new products it stands at ₹3000-3500mn.
- Production volumes Update: Nitro-Chloro-Benzene, volumes were up ~20,347MT vs. 17,830MT; Hydrogenated products: ~2,712MT vs. 3,038MT; Nitro-Toluene: ~3,772MT vs. 4,119MT; and PDA segment: 458tonnes vs. 470tonnes.

### **Key Risks**

Slower than expected demand recovery in its key markets and 3<sup>rd</sup> wave of Covid -19.

Financials				
			<i>(₹ mn)</i>	
Particulars	FY19	FY20	FY21	
Net Sales	41,676	41,863	45,061	
EBITDA	9,651	9,773	9,815	
EBITDAM%	23.2%	23.3%	21.8%	
PAT	4,917	5,361	5,235	
PATM%	11.8%	12.8%	11.9%	
EPS (₹)	28.2	30.8	30.7	
ROE (%)	18.1%	17.4%	15.2%	
ROCE (%)	16.9%	16.5%	12.5%	
P/E (x)	33.3	30.5	30.6	
EV/EBITDA (x)	18.3	18.3	18.8	

Source: Company Filing, Way2wealth Research

W2W Lighthouse - A Quick Perspective

Aarti Industries Ltd.

**Important Statistics** 

M.Cap (₹ Cr)	₹35204
52 Week H/L (₹)	1168/495
NSE Code	AARTI IND
BSE Code	524208

Shareholding pattern (%)	Sep'21
Promoter Holding	44.21
FII	4.4
DII	20.6
Public	37.6

Way2Wealth	
Research	


Way2Wealth Brokers Pvt. Ltd. (CIN U67120KA2000PTC027628) SEBI Rgn. No.: INH200008705.

Registered Office: Rukmini Towers, 3<sup>rd</sup>& 4<sup>th</sup> Floor, # 3/1, Platform Road, Sheshadripuram, Bangalore - 560 020, Website: www.way2wealth.com Email: research@way2wealth.comWay2wealth Research is also available on Bloomberg WTWL<GO>



#### View

Company showcased good performance in Q2FY22 driven by both pharmaceuticals and specialty chemicals segment, higher contribution from value-added products and demand recovery in its markets. The management has maintained a revenue/PAT growth guidance of 25-35% for FY22, despite significant inflation in RM/logistics/fuel costs, given the strong demand from local customers. We are bullish on the growth prospects of the company driven by higher contribution from value added products, two long term contracts, strong growth outlook for the Indian specialty chemical sector supported by the China+1 strategy by global companies and robust growth from pharmaceuticals. Company's sustained leadership, superior return ratios, strong balance sheet further boosts our confidence. At CMP of ₹939, Aarti Industries Ltd trades at ~30 FY21 EPS and ~19x FY21 EV/EBITDA but is justified given its long-term growth story thus we recommend investors to 'ACCUMULATE on Dips'.



Source: Company Filing, Way2wealth Research

					(₹ mn)
Particulars	Q2FY22	Q1FY22	Q2FY21	Y-o-Y	Q-o-Q
Revenue	15,516	13,168	11,726	32.3%	17.8%
Cost of raw material consumed	8,220	6,101	5,781	42.2%	34.7%
Employee expense	989	995	935	5.8%	-0.6%
Other expense	3,209	2,934	2,467	30.1%	9.4%
Total expenditure	12,418	10,030	9,184	35.2%	23.8%
EBITDA	3,098	3,138	2,543	21.8%	-1.3%
EBITDA Margin	20.0%	21.5%	21.7%	(161 bps)	(71 bps)
Dep	711	686	550	29.2%	3.6%
EBIT	2,387	2,452	1,993	19.8%	-2.7%
EBIT Margin	15.4%	16.1%	17.0%	(161 bps)	(71 bps)
Interest	185	383	222	-16.6%	-51.7%
other income	5	1	0	NA	NA
EBT	2,208	2,070	1,772	24.6%	6.7%
tax	447	419	337	32.8%	6.7%
РАТ	1,761	1,651	1,435	22.7%	6.6%
PAT Margin	11.3%	11.2%	11.6%	(26 bps)	15 bps
EPS (₹)	4.86	4.55	8.05	-39.7%	6.6%

Source: Company Filing, Way2wealth Research

### Way2Wealth Research

Way2Wealth Brokers Pvt. Ltd. (CIN U67120KA2000PTC027628) SEBI Rgn. No.: INH200008705.

Registered Office: Rukmini Towers, 3ª& 4ª Floor, # 3/1, Platform Road, Sheshadripuram, Bangalore - 560 020, Website: www.way2wealth.com Email: research@way2wealth.com**Way2wealth Research is also available on Bloomberg WTWL<GO>** 

## Sector - Chemicals

Research Desk 🗢

# Aarti Industries Ltd.

**Light House Update** 

12th November 2021

#### CMP – ₹939/-

View – Accumulate on dips

#### Disclaimer

Analyst Certification: I, Yogita Desai, the research analyst and author of this report, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s), principally responsible for the preparation of this research report, receives compensation based on overall revenues of the company (Way2Wealth Brokers Private Limited, hereinafter referred to as Way2Wealth) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

It is confirmed that Yogita Desai, the author of this report has not received any compensation from the companies mentioned in the report in the preceding 12 months. Our research professionals are paid in part based on the profitability of Way2Wealth, which include earnings from other business. Neither Way2Wealth nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information contained in this report.

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Way2Wealth is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. The contents of this material are general and are neither comprehensive nor appropriate for every individual and are solely for the informational purposes of the readers. The material does not take into account the specific objectives, financial situation or needs of an individual/s or a Corporate/s or any entity/s.

This research has been prepared for the general use of the clients of the Way2Wealth and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient, you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Way2Wealth will not treat recipients as customers by virtue of their receiving this report. The distribution of this document in other jurisdictions may be restricted by the law applicable in the relevant jurisdictions and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The report is based upon information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up to date and it should not be relied upon as such. Way2Wealth or any of its affiliates or employees makes no warranties, either express or implied of any kind regarding any matter pertaining to this report, including, but not limited to warranties of suitability, fitness for a particular purpose, accuracy, timeliness, completeness or non-infringement. We accept no obligation to correct or update the information or opinions in it. Way2Wealth or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. The recipients of this report should rely on their own investigations. In no event shall Way2Wealth be liable for any damages of any kind, including, but not limited to, indirect, special, incidental, consequential, punitive, lost profits, or lost opportunity, whether or not Way2Wealth has advised of the possibility of such damages.

This material contains statements that are forward-looking; such statements are based upon the current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These uncertainties include but are not limited to: the risk of adverse movements or volatility in the securities markets or in interest or foreign exchange rates or indices; adverse impact from an economic slowdown; downturn in domestic or foreign securities and trading conditions or markets; increased competition; unfavorable political and diplomatic developments; change in the governmental or regulatory policies; failure of a corporate event and such others. This is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. No part of this material may be copied or duplicated in any form by any means or redistributed without the written consent of Way2Wealth. In no event shall any reader publish, retransmit, redistribute or otherwise reproduce any information provided by Way2Wealth in any format to anyone. Way2Wealth and its affiliates, officers, directors and employees including persons involved in the preparation or issuance of this report may from time to time have interest in securities / positions, financial or otherwise in the securities related to the information contained in this report.

To enhance transparency, Way2Wealth has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

#### Disclosure of Interest Statement Aarti Industries Ltd. as on November 12th, 2021

Aarti	Aarti Industries Ltd.
Name of the analyst	Yogita Desai
Analysts' ownership of any stock related to the information contained	NIL
Financial Interest	
Analyst :	No
Analyst's Relative : Yes / No	No
Analyst's Associate/Firm : Yes/No	No
Conflict of Interest	No
Receipt of Compensation	No
Way2Wealth ownership of any stock related to the information contained	NIL
Broking relationship with company covered	NIL
Investment Banking relationship with company covered	NIL

This information is subject to change without any prior notice. Way2Wealth reserves at its absolute discretion the right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, Way2Wealth is committed to providing independent and transparent recommendations to its clients and would be happy to provide information in response to specific client queries.

Way2Wealth Research Way2Wealth Brokers Pvt. Ltd. (CIN U67120KA2000PTC027628) SEBI Rgn. No.: INH200008705.

Registered Office: Rukmini Towers, 3<sup>ad</sup>& 4<sup>th</sup> Floor, # 3/1, Platform Road, Sheshadripuram, Bangalore - 560 020, Website: www.way2wealth.com Email: research@way2wealth.com**Way2wealth Research is also availa<u>ble on Bloomberg WTWL<GO></u>**